Amgen's Tezspire meets all endpoints in phase 3 esophagitis trial
Amgen (NASDAQ: AMGN) and AstraZeneca announced positive top-line results from the phase 3 CROSSING trial of Tezspire (tezepelumab-ekko) in patients ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)